{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RO5424802&page=2", "query": { "intervention": "RO5424802", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RO5424802&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T19:26:51.754Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Solid Tumors", "Biliary Cancer", "Salivary Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 673, "start_date": "2014-04-14", "completion_date": "2023-05-24", "has_results": true, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 60, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091141" }, { "nct_id": "NCT04634110", "title": "Brigatinib Before Brain Irradiation Trial (B3i Trial)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases", "Lung Cancer" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-11-17", "completion_date": "2022-04-14", "has_results": true, "last_update_posted_date": "2022-10-24", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 3, "location_summary": "Duarte, California • Aurora, Colorado • Rochester, Minnesota", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634110" }, { "nct_id": "NCT04589845", "title": "Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Belvarafenib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" }, { "name": "Camonsertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 920, "start_date": "2021-01-18", "completion_date": "2032-09-25", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 32, "location_summary": "Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589845" }, { "nct_id": "NCT05170204", "title": "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2022-11-01", "completion_date": "2030-06-16", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 2, "location_summary": "Tigard, Oregon • Pittsburgh, Pennsylvania", "locations": [ { "city": "Tigard", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05170204" }, { "nct_id": "NCT02706626", "title": "Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "brigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Criterium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-03-09", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 4, "location_summary": "Denver, Colorado • Durham, North Carolina • Nashville, Tennessee + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706626" }, { "nct_id": "NCT03546894", "title": "A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anaplastic Lymphoma Kinase-positive", "Carcinoma Non-small-cell Lung" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Any FDA Approved ALK Inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-07-23", "completion_date": "2023-02-13", "has_results": false, "last_update_posted_date": "2024-07-15", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 1, "location_summary": "Maynard, Massachusetts", "locations": [ { "city": "Maynard", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03546894" }, { "nct_id": "NCT01871805", "title": "A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2013-09-30", "completion_date": "2017-08-31", "has_results": true, "last_update_posted_date": "2018-08-21", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Irvine, California • La Jolla, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871805" }, { "nct_id": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Colorectal Neoplasms", "Melanoma", "Pancreatic Neoplasms", "Sarcoma", "Ovarian Neoplasms", "Brain Neoplasms", "Thyroid Neoplasms", "Neuroendocrine Tumors", "Cholangiocarcinoma", "Salivary Gland Neoplasms", "Head and Neck Neoplasms", "Thyroid Cancer, Papillary", "Lymphoma, Large-Cell, Anaplastic", "Neoplasms by Site", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Central Nervous System" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-24", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 29, "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644315" }, { "nct_id": "NCT06765109", "title": "Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "Anaplastic Lymphoma Kinase-positive" ], "interventions": [ { "name": "Neladalkib (NVL-655)", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvalent Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2025-07-17", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 23, "location_summary": "Glendale, Arizona • Newport Beach, California • Orange, California + 19 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06765109" }, { "nct_id": "NCT05987644", "title": "Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "NSCLC", "Brain Metastases" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Joshua Palmer", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2024-03-07", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-09-18T19:26:51.754Z", "location_count": 3, "location_summary": "Stanford, California • Aurora, Colorado • Columbus, Ohio", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987644" } ] }